Important Safety Information Prescribing Information This website is intended for US residents only.
Sancuso Logo
Sancuso patch

SANCUSO®
(granisetron transdermal system) keeps them covered

For the prevention of nausea and vomiting in patients receiving moderately and/​or highly emetogenic chemotherapy regimens of up to 5 consecutive days1

Think SANCUSO first

SANCUSO helps prevent chemotherapy-induced nausea and vomiting (CINV) in patients with cancer who are mechanically compromised and/​or who may be unable to take or retain oral antiemetics1,2,a,b

Consider SANCUSO for patients like the following who are struggling with CINV:

Sancuso may be helpful for patients on oral chemotherapy Patients receiving oral chemotherapy3
Breast cancer awareness icon Patients with breast cancer3
Consider Sancuso for patients with previous breakthrough symptoms Patients with previous breakthrough symptoms3
Patients with CINV may be mechanically compromised
Patients who are mechanically compromised2
Forgetfulness associated with CINV may be helped by Sancuso Patients who are forgetful4
Learn more about SANCUSO

SANCUSO patch price guarantee

Guarantee your commercially insured patients get at least 1 SANCUSO patch per month for $20

Learn More

This offer is not valid for prescriptions under Medicare (including Medicare Advantage, Part A, B, and D plans), Medicaid, VA, DOD, TRICARE, CHAMPUS, or other federal or state healthcare programs. This offer is not valid for prescriptions in Massachusetts or in any other state that does not permit copay reimbursement consistent with this program. Patients without commercial insurance are not eligible for this program. Unless otherwise indicated on the submission form, SANCUSO will be dispensed through select pharmacies in the ASPN network. Kyowa Kirin, Inc., reserves the right to cancel or modify the program at any time. Offer expires December 31, 2020.

Evaluating patients

Play video

Keep your patients covered

You may have patients with CINV who are ready for SANCUSO. Now you can receive updates about SANCUSO and learn about new resources as they become available.

Stay informed
  1. SANCUSO is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.1
  2. Patients with cancer who are mechanically compromised include those with oral and/or gastrointestinal impairment associated with chemotherapy, with orwithout radiation, or tumor burden, and who may be unable to take or retain oral antiemetics.2
Indication and Important Safety Information

Indication

SANCUSO® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.

Important Safety Information

Contraindications

SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.

Warnings and Precautions

Adverse Reactions

The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).

To report suspected adverse reactions, contact Kyowa Kirin, Inc. at 1-800-SANCUSO or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See full Prescribing Information for SANCUSO.

References:
  1. SANCUSO [package insert]. Bridgewater, NJ: Kyowa Kirin, Inc.; 2013.
  2. Schulmeister L. Granisetron transdermal system: a new option to help prevent chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs. 2009;13(6):711-714. doi:10.1188/09.CJON.711-714.
  3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Antiemesis. National Comprehensive Cancer Network. https://​www.nccn.org/​professionals/​physician_gls/​pdf/​antiemesis.pdf. Updated July 20, 2011. Accessed December 18, 2019.
  4. Chemo brain. American Cancer Society website. http://​www.cancer.org/​treatment/​treatments-and-side-effects/​physical-side-effects/​changes-in-mood-or-thinking/​chemo-brain.html. Updated June 9, 2016. Accessed December 18, 2019.